How many “different” types of prostate cancer are there?

This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …

Standardizing outcome measures in management of advanced prostate cancer

The Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement has finally been able to pull together a set of standardized patient-centered outcomes relevant to the evaluation of men in treatment for advanced forms of prostate cancer. … READ MORE …

Radiation therapy may improve survival even when PSA ≥ 75 ml/ml

Sometimes, when patients originally present with very high PSA levels, a negative bone scan, and a negative CT scan, they are put on permanent androgen deprivation  therapy (ADT) because the doctor just assumes it is micrometastatic. … READ MORE …

Docetaxel with radiation in prostate cancer treatment

In 2004, the FDA approved docetaxel as the first chemotherapy drug proven to extend survival in metastatic hormone-refractory prostate cancer. Although the survival benefit was a modest 2.5 months, researchers launched clinical trials to determine whether the survival advantage could be increased … READ MORE …

TARP trial shows limited benefits from 5-ARI + an anti-androgen in CRPC

For some 15+ years there have been subsets of patients and physicians who have believed strongly that adding a 5α-reductase inhibitor (5-ARI) like finasteride or dutasteride to an anti-androgen would quite certainly aid in the prevention of prostate cancer progression because such a regimen would reduce levels of dihydrotestosterone. … READ MORE …

Risk factors for primary radiation failure and timing of progression

Zumsteg et al. searched the database at Memorial Sloan-Kettering Cancer Center (MSKCC) to determine the risk factors associated with cancer progression after primary radiation treatment, and the timing of progression. They report their results in European Urology, … READ MORE …

New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers